Streetbeat News

Products Services

NVS

VGK

Sandoz, a unit of Novartis, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for marketing authorization for its biosimilar natalizumab. The authorization covers treatment for adults with highly active relapsing-remitting multiple sclerosis.

Portfolio Pulse from Charles Gross

July 24, 2023 | 8:53 am

ADDYY

Adidas has secured $565 million in orders for the first batch of unsold Yeezy shoes, according to the Financial Times.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 7:42 am

TSLA

A Twitter user claimed to have purchased a Tesla Model 3 for under $15,000 before taxes and fees, thanks to a combination of rebates, federal tax credits, and a discount from inventory. The base Model 3 starts at $40,240 and qualifies for a $7,500 credit, along with all other versions of the vehicle. However, Tesla has begun warning potential customers that the tax credit may be reduced starting next year.

Portfolio Pulse from Anan Ashraf

July 24, 2023 | 7:09 am

ADXN

Addex Therapeutics has announced data showing the administration of a Metabotropic Glutamate 2 (mGlu2) Positive Allosteric Modulator. The specific impacts of this data on the company's operations or financials were not detailed in the article.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 6:23 am

TSLA

Elon Musk, CEO of Tesla, expressed surprise at the general public's lack of awareness about Tesla's Full Self-Driving (FSD) technology. This comes after Tesla's recent announcements about the future of its FSD technology, including a one-off amnesty for customers to transfer their FSD software to a new vehicle and the upcoming release of FSD version 12. Tesla is also in early discussions to license its self-driving technology to a major automaker.

Portfolio Pulse from Benzinga Neuro

July 24, 2023 | 6:00 am

ALNY

RHHBY

Alnylam Pharmaceuticals has partnered with Roche to develop and commercialize Zilebesiran, Alnylam's investigational RNAi therapeutic for hypertension treatment. Alnylam will receive an upfront cash payment of $310 million and is eligible for development, regulatory, and sales milestones, potentially valuing the deal at up to $2.8 billion. The companies will share profits and losses equally in the US, and Alnylam will receive royalties on net sales outside the US.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 5:53 am

STLA

Stellantis and Samsung SDI have announced plans to build a second StarPlus Energy Gigafactory in the US, with an initial annual production capacity of 34 GWh.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 5:46 am

GILD

Gilead Sciences has announced results from multiple studies that reinforce Biktarvy as a treatment option for a broad range of people with HIV.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2023 | 5:33 am

AAPL

AMZN

DIS

META

NFLX

Apple's first-generation mixed-reality headset, the Vision Pro, has attracted significant attention, with Disney+ confirmed for the platform and Amazon Prime Video likely to follow. However, Netflix has decided against developing a native app for the headset due to the relatively smaller market for the Vision Pro compared to other Apple devices. Despite this, the potential of the Vision Pro is not to be underestimated, with the possibility of app prices surging beyond traditional norms.

Portfolio Pulse from Ananya Gairola

July 24, 2023 | 4:12 am

BTCUSD

ETHUSD

A token unrelated to Elon Musk's X.com has seen a surge of 1800% within 24 hours, following Musk's hint at a logo change for Twitter. The token is a project by X, a decentralized NFT marketplace. Musk's acquisition of Twitter earlier this year led to its integration into X Corp., a privately-held corporation. Bitcoin was trading at $29,774, down 0.24% in the last 24 hours.

Portfolio Pulse from Mehab Qureshi

July 24, 2023 | 3:44 am